Sangamo Therapeutics Announces Global Epigenetic Regulation and Capsid Delivery License Agreement with Genentech to Develop Novel Genomic Medicines for Neurodegenerative Diseases
06 Agosto 2024 - 7:05AM
Business Wire
- Agreement leverages Sangamo’s proprietary capsid delivery
platform and epigenetic regulation capabilities to address certain
neurodegenerative diseases
- Sangamo expected to receive $50 million in near-term upfront
license fees and milestone payments and is eligible to earn up to
$1.9 billion in development and commercial milestone payments
across multiple medicines, as well as tiered royalties on net
sales
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a
genomic medicine company, today announced it has entered into a
license agreement with Genentech, a member of the Roche Group, to
develop intravenously administered genomic medicines to treat
certain neurodegenerative diseases. Sangamo has granted Genentech
an exclusive license to Sangamo’s proprietary zinc finger
repressors that are directed to the tau gene, which is critically
involved in Alzheimer’s disease and other tauopathies, as well as
an undisclosed second neurology target. Sangamo has also agreed to
exclusively license to Genentech, for tau and the second neurology
target, Sangamo’s proprietary, neurotropic adeno-associated virus
(AAV) capsid, STAC-BBB, which has demonstrated potent blood-brain
barrier penetration and brain transduction in nonhuman
primates.
“Sangamo has been pioneering the field of genomic medicine for
years to address devastating neurodegenerative diseases with
limited current treatment options,” said Sandy Macrae, Chief
Executive Officer of Sangamo. “We strongly believe in the power of
our zinc finger technology to regulate the expression of key genes
involved in disease. The recent discovery of our industry-leading
intravenously delivered AAV capsid, STAC-BBB, has the potential to
address longstanding challenges in delivering therapeutics to the
central nervous system. We are excited to share this powerful
combination with Genentech to advance potential treatment options
for devastating neurodegenerative disorders, and we are hopeful
this could be the first of multiple capsid collaborations to come
with other partners.”
“We are uniquely positioned with our collective experience,
expertise and resources in neurological research to explore
transformative approaches, including gene therapy, that treat
neurodegenerative diseases,” said Boris L. Zaïtra, Head of Roche
Corporate Business Development. “Through groundbreaking research
and partnerships with companies such as Sangamo, we are committed
to pursuing important breakthroughs in both early diagnosis and
treatment. Our relentless pursuit of scientific innovation is
taking us into areas of enormous unmet medical need and progress in
treating diseases of the brain and nervous system.”
Under the terms of the agreement, Sangamo is responsible for
completing a technology transfer and certain preclinical
activities, and Genentech is responsible for all clinical
development, regulatory interactions, manufacturing and global
commercialization. Genentech is expected to pay Sangamo $50 million
in near-term upfront license fees and milestone payments. Sangamo
is eligible to earn up to $1.9 billion in development and
commercial milestones spread across multiple potential products
under the agreement and tiered royalties on net sales of such
products, subject to certain specified reductions.
Sangamo continues to engage in business development discussions
with additional potential collaboration partners about the Sangamo
STAC-BBB capsid delivery platform, its epigenetic regulation
capabilities, and other assets, including Fabry disease.
About Sangamo Therapeutics
Sangamo Therapeutics is a genomic medicine company dedicated to
translating ground-breaking science into medicines that transform
the lives of patients and families afflicted with serious
neurological diseases who do not have adequate or any treatment
options. Sangamo believes that its zinc finger epigenetic
regulators are ideally suited to potentially address devastating
neurological disorders and that its capsid discovery platform can
expand delivery beyond currently available intrathecal delivery
capsids, including in the central nervous system. Sangamo’s
pipeline also includes multiple partnered programs and programs
with opportunities for partnership and investment. To learn more,
visit www.sangamo.com and connect with us on LinkedIn and
Twitter/X.
Sangamo Forward Looking Statements
This press release contains forward-looking statements based on
Sangamo's current expectations. These forward-looking statements
include, without limitation, statements relating to the potential
for Genentech to develop intravenously administered genomic
medicines to treat neurodegenerative diseases by leveraging
Sangamo’s epigenetic regulation and capsid delivery capabilities,
the potential for STAC-BBB to address challenges in delivering
therapeutics to the central nervous system, the potential of
Sangamo’s capsids to deliver therapies treating neurological
diseases, expectations concerning Sangamo’s completion of the
requisite technology transfer and capsid optimization activities,
the potential for Genentech to complete clinical development,
regulatory interactions, manufacturing and global commercialization
of any resulting products, expectations concerning Sangamo’s
receipt of an upfront license fee and near-term milestone payments
and the timing thereof, the potential for Sangamo to receive
development and commercial milestone payments and royalties, plans
and expectations concerning additional collaborations with respect
to Sangamo’s STAC-BBB capsid delivery platform, epigenetic
regulation capabilities, and other assets, and other statements
that are not historical fact. These statements are not guarantees
of future performance and are subject to certain risks and
uncertainties that are difficult to predict. Factors that could
cause actual results to differ include, but are not limited to, the
research and development process, including the results of
preclinical studies and clinical trials; the regulatory approval
process for product candidates; the potential for technological
developments that obviate technologies used by Sangamo and its
partners; the potential for Genentech to breach or terminate its
agreement with Sangamo; and the potential for Sangamo to fail to
realize its expected benefits from the Genentech agreement,
including but not limited to further validating the importance of
the zinc finger platform to support the development of therapeutics
for neurodegenerative diseases; Sangamo’s inability to secure
additional collaboration partners; and Sangamo’s need for
substantial additional funding to operate as a going concern. There
can be no assurance that Sangamo will earn any milestone or royalty
payments under the Genentech agreement or obtain regulatory
approvals for product candidates arising from this agreement.
Actual results may differ from those projected in forward-looking
statements due to risks and uncertainties that exist in Sangamo's
and Genentech’s operations and businesses. These risks and
uncertainties are described more fully in Sangamo’s Securities and
Exchange Commission, or SEC, filings and reports, including in its
Annual Report on Form 10-K for the year ended December 31, 2023, as
supplemented by its Quarterly Report on Form 10-Q for the quarter
ended March 31, 2024, each filed with the SEC, and future filings
and reports that Sangamo makes from time to time with the SEC.
Forward-looking statements contained in this announcement are made
as of this date, and Sangamo undertakes no duty to update such
information except as required under applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240806084723/en/
Investor Relations & Media Inquiries Louise Wilkie
ir@sangamo.com media@sangamo.com
Sangamo Therapeutics (NASDAQ:SGMO)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Sangamo Therapeutics (NASDAQ:SGMO)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024